MAPK1 and melanoma: Immunoblotting confirmed the specific targeting of CAPN1 by shRNAs, NF1 stabilization, as well as a reduction in pAKT-308 and pAKT-473 in both melanoma cell lines, while ERK activation remained unchanged (Figure 4B).